London-based clinic MyBreast Cosmetic Surgery has been chosen as the only UK clinic to participate in an international clinical trial to determine the safety and effectiveness of a number of breast implants including the SmoothSilk, Round and Ergonomix from Motiva Implants.
The Food and Drug Administration (FDA) has approved Jeuveau, a botulinum toxin type A, for the temporary improvement in the appearance of moderate to severe glabellar lines.
A recent BBC Panorama programme has highlighted the need for stricter regulations around the use of medical devices in the healthcare sector.
Preliminary guidelines for the off-label use of calcium hydroxylapatite (CaHA) for biostimulation in the face and body has been published in Dermatologic Surgery.
The US Food and Drug Administration (FDA) has approved hyaluronic acid dermal filler Restylane Lyft for cheek augmentation and the correction of age-related mid-face contour deficiencies via small blunt tip cannula in patients over the age of 21.
International pharmaceutical company Galderma has increased its investment in research and innovation, initiating six new Phase III and IV US aesthetic clinical trials.
The National Institute for Health and Care Excellence (NICE) has approved a drug combination of dabrafenib with trametinib for treating patients who have previously been affected by skin cancer, melanoma.
A study published by the Journal of Investigative Dermatology has revealed promising results for a new vaccine that could prevent acne vulgaris.
Skincare and supplement company ZENii has added two new vegan skin-focused supplements to its professional range.
The Food and Drug Administration (FDA) has cleared the CustomFlex Artificial in the US, a prosthetic iris that is surgically implanted to treat adults and children whose iris is damaged or missing due to aniridia (a congenital condition) or other damages to the area.